13F Holdings
中文EN

CYTOF Altamira Therapeutics Ltd. IFRS Annual reports only

Pharmaceutical Preparations · OTC · SEC CIK 1601936 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-128.8%
ROA-97.8%
ROIC (approx.)-97.2%
Asset turnover—

Leverage & solvency

Liabilities / assets24.1%
Debt / equity0.00x
Current ratio1.32x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.72x
Accruals ratio-27.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY2024*2024-12-31 · USDFY20232023-12-31 · CHFFY20232023-12-24 · CHFFY20222022-12-31 · CHFFY20222022-12-24 · CHF
Income statement
Revenue—379—305,616—
Cost of revenue—33,967—1.44M—
Gross profit—-33,588—-1.14M—
R&D expense$3.73M3.04M—14.62M—
SG&A expense$3.20M3.14M—3.40M—
Operating income-$6.85M-5.92M—-18.01M—
Interest expense$01.01M—911,869—
Pretax income-$8.46M-7.27M—-18.66M—
Income tax———-7,919—
Net income-$8.46M-3.87M—-26.53M—
EPS (basic)-2.99-7.88—-582.58—
EPS (diluted)-2.99-7.88—-582.58—
Weighted avg. shares (diluted)451,55541,803—910,723—
Balance sheet
Cash & equivalents$998,624617,409—15,395—
Receivables———6,525—
Inventory———11,644—
Current assets$1.54M1.22M—1.77M—
PP&E, netmay include right-of-use assets (IFRS)$100,0001—1—
Intangibles$4.63M3.89M—3.89M—
Total assets$8.65M7.69M—6.30M—
Current liabilities$1.16M888,914—12.88M—
Short-term debt———5.87M—
Total liabilities$2.09M1.24M—14.62M—
Shareholders' equity$6.57M6.46M—-8.31M—
Shares outstanding4.66M1.48M—59,003—
Cash flow statement
Operating cash flow-$6.11M-$12.81MUSD—-$9.09MUSD—
Capital expenditure$103,087————
Free cash flow-$6.22M————
Investing cash flow-$115,3411.44M—-2.14M—
Financing cash flow$6.51M10.62M—9.83M—
Stock-based compensation$532,081379,414—342,799—

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.